Imaging against multiple sclerosis: Iodinated radiotracer candidate for PET and SPECT imaging

February 4, 2011

( -- A first-line treatment for relapsing forms of multiple sclerosis (MS) was approved in September 2010 by the US Food and Drug Administration: FTY720 (fingolimod, Gilenya), which acts as a sphingosine 1-phosphate (S1P) receptor modulator.

There is preclinical evidence that in addition to decreasing infiltration of lymphocytes into the (CNS), FTY720 may provide additional neuroprotection through modulation of cerebral S1P receptors.

To further study the action of FTY720 in the CNS, Emmanuelle Briard, Yves Auberson, and colleagues at the Institutes for BioMedical Research in Basel (Switzerland) evaluated a series of iodinated FTY720 derivatives that could be used to study the drug's brain distribution in patients using nuclear imaging techniques, and their results are reported in ChemMedChem.

After extensive profiling, they identified 2-iodo-FTY720 (BZM055) as a close mimic of FTY720, having similar physicochemical properties and organ distribution, despite the addition of an iodine atom. They also showed that BZM055 is phosphorylated into its biologically active form at a similar rate to FTY720, retaining an affinity and selectivity for S1P receptors comparable to FTY720-phosphate, as well as similar brain penetration kinetics.

[123I]BZM055 is currently being developed as a SPECT tracer for studying the pharmacokinetics and distribution of FTY720 in the human . In addition, and since FTY720 has been shown to accumulate in myelin sheaths, this tracer might also prove useful to image myelin in MS patients.

Explore further: Novel mechanism of action of new drug for MS identified

More information: Emmanuelle Briard, BZM055, an Iodinated Radiotracer Candidate for PET and SPECT Imaging of Myelin and FTY720 Brain Distribution, ChemMedChem, Permalink to the article:

Related Stories

Caffeine prevents multiple sclerosis-like disease in mice

April 7, 2008

Mice given caffeine equivalent to a human drinking six to eight cups of coffee a day were protected from developing experimental autoimmune encephalomyelitis (EAE), the animal model for the human disease Multiple Sclerosis ...

A biotherapy strategy for esophageal cancer in the future

April 19, 2010

A research team from China focused on esophageal squamous cell carcinoma (ESCC) and characterized sphingosine 1-phosphate (S1P) receptor expression pattern and investigated the role of S1P receptors on ESCC cells proliferation ...

New treatment to overpower drug resistance in ovarian cancer

November 15, 2010

Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism. ...

Recommended for you

A new form of real gold, almost as light as air

November 25, 2015

Researchers at ETH Zurich have created a new type of foam made of real gold. It is the lightest form ever produced of the precious metal: a thousand times lighter than its conventional form and yet it is nearly impossible ...

Moonlighting molecules: Finding new uses for old enzymes

November 27, 2015

A collaboration between the University of Cambridge and MedImmune, the global biologics research and development arm of AstraZeneca, has led researchers to identify a potentially significant new application for a well-known ...

Atom-sized craters make a catalyst much more active

November 24, 2015

Bombarding and stretching an important industrial catalyst opens up tiny holes on its surface where atoms can attach and react, greatly increasing its activity as a promoter of chemical reactions, according to a study by ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.